Beranda › Karsinoma Nasofaring
Uji klinis Karsinoma Nasofaring yang merekrut di AS
13 studi untuk Karsinoma Nasofaring merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Atlanta, GA6 studi
- Chicago, IL3 studi
- Cincinnati, OH3 studi
- Richmond, VA3 studi
- Los Angeles, CA3 studi
- Charlotte, NC3 studi
- Pittsburgh, PA3 studi
- Washington, DC3 studi
- San Francisco, CA3 studi
- Milwaukee, WI3 studi
- Oklahoma City, OK3 studi
- Houston, TX3 studi
Berdasarkan negara bagian
- California6 studi
- Georgia6 studi
- Illinois3 studi
- Maryland3 studi
- Missouri3 studi
- North Carolina3 studi
- Ohio3 studi
- Oklahoma3 studi
- Pennsylvania3 studi
- South Carolina3 studi
- Texas4 studi
- Virginia4 studi
- Wisconsin3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Menerima pesertaFase 2
Hingga usia 21 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT06636734Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.